We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

PerkinElmer Unveils Industry-First Cell Analysis Solution


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "PerkinElmer Unveils Industry-First Cell Analysis Solution"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

PerkinElmer, Inc., (NYSE: PKI), has launched the Cellaca® PLX Image Cytometry System, a first-of-its-kind benchtop platform that enables researchers to assess multiple Critical Quality Attributes (CQAs) of cell samples in a single automated workflow, including cell identity, quality and quantity.


The cutting-edge Cellaca PLX system, designed by the company’s Nexcelom unit, combines best-in-class image cytometer hardware, software, validated consumables and trackable data reporting all in one system without requiring complex calibration procedures or intense training requirements. To further streamline the customer experience, optimized reagent kits with validated antibodies from PerkinElmer’s BioLegend business are also part of the proprietary solution.


The new offering provides researchers expanded cell sample CQA analysis options beyond flow cytometry and staining methods, which historically have required a variety of different instruments and analytical methods. By combining these capabilities, researchers can now detect multiple markers simultaneously (multiplexing) and perform immunophenotyping and viability assays in seconds with an easy-to-use, modern user interface.


"Pharmaceutical companies have invested heavily in cell and gene therapy, but they struggle to assess the complex cell samples required to meet immense scientific demands and regulatory rigor across their research and manufacturing processes," said Alan Fletcher, senior vice president, Life Sciences, PerkinElmer. "While the Cellaca PLX Image Cytometer platform is therapeutic area agnostic, it is expected to be especially beneficial for researchers working in CAR-T cell therapy who want to streamline their phenotyping of immune cells for downstream processes."


Learn more about the new platform and other image cytometry instruments and reagents at BioProcessing International East from September 27-30 in Boston where PerkinElmer is showcasing the latest innovations across its extensive Life Science and cell and gene therapy portfolio in booths 625 and 631. Product demonstrations can be scheduled here.

Advertisement